CN114209723A - Composition for assisting in reducing blood fat, product containing composition and application - Google Patents
Composition for assisting in reducing blood fat, product containing composition and application Download PDFInfo
- Publication number
- CN114209723A CN114209723A CN202111657410.XA CN202111657410A CN114209723A CN 114209723 A CN114209723 A CN 114209723A CN 202111657410 A CN202111657410 A CN 202111657410A CN 114209723 A CN114209723 A CN 114209723A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- extract
- composition
- pseudo
- assisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 50
- 239000008280 blood Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000001603 reducing effect Effects 0.000 title claims abstract description 33
- 235000008434 ginseng Nutrition 0.000 claims abstract description 66
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 64
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 64
- 238000000605 extraction Methods 0.000 claims abstract description 59
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 54
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 14
- 238000007908 dry granulation Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- 239000000284 extract Substances 0.000 claims description 47
- 239000000243 solution Substances 0.000 claims description 34
- 241000180649 Panax notoginseng Species 0.000 claims description 33
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 33
- 235000020710 ginseng extract Nutrition 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 7
- 238000007599 discharging Methods 0.000 claims description 6
- 229930182494 ginsenoside Natural products 0.000 claims description 6
- 229940089161 ginsenoside Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011362 coarse particle Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 239000009277 Panax notoginseng extract Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000000859 sublimation Methods 0.000 claims description 4
- 230000008022 sublimation Effects 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000012675 alcoholic extract Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 229930182490 saponin Natural products 0.000 abstract description 25
- 150000007949 saponins Chemical class 0.000 abstract description 25
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 13
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 238000012545 processing Methods 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 description 50
- 235000017709 saponins Nutrition 0.000 description 22
- 235000019197 fats Nutrition 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 8
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000012141 vanillin Nutrition 0.000 description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 description 2
- 102100026841 Sterol regulatory element-binding protein 2 Human genes 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition for assisting in reducing blood fat, a product containing the composition and application. The ginseng and the pseudo-ginseng have good auxiliary blood fat reducing effect, the main active parts of the ginseng and the pseudo-ginseng are saponin components, and the probability of moisture absorption and degradation of the saponin active components can be effectively reduced by adopting dry granulation. In order to provide the active ingredient for reducing blood fat with better processing performance, the invention optimizes the extraction process of the saponin ingredients in the medicinal materials and provides a composition which has better drug effect activity and is more suitable for dry granulation.
Description
Technical Field
The invention belongs to the technical field of natural medicine extracts, and particularly relates to a composition for assisting in reducing blood fat, a product containing the composition and a method for assisting in reducing blood fat.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
Ginseng is a natural tonic, has the effects of treatment, health care, nourishing and body building and the like, mainly comprises ginsenoside, polypeptide, polysaccharide and the like, and is widely applied to the preparation of anti-tumor drugs, cardiovascular and cerebrovascular system protection drugs, nervous system protection drugs, liver injury prevention drugs and antiviral drugs at present.
Modern researches have proved that ginseng has a prominent effect in reducing blood lipid. The research results of the reported influences of ginseng on the hepatic lipid metabolism disorder of the mice with hyperlipidemia indicate that the ginseng with high, medium and low doses can effectively reduce the liver coefficient of the mice with hyperlipidemia, and simultaneously reduce the contents of LDL-C, ALT and TG in serum to realize the efficacy of reducing blood lipid. In the research of exploring ginseng total saponins from Liuwei to reduce blood fat of rats, research results show that the ginseng total saponins can obviously reduce the serum TG and TC contents of the rat with hyperlipidemic hypercholesterolemia, and the ginseng total saponins have the function of reducing blood fat.
Notoginseng radix, belonging to Panax genus of Araliaceae family, is a common clinical Chinese medicine with effects of stopping bleeding, relieving pain, relieving swelling, dispelling blood stasis, tonifying deficiency, strengthening body etc., and has effects of reducing blood cholesterol and blood lipid by using saponins, volatile oil, amino acids, flavonoids, organic acids etc. as main ingredients. Research on the blood lipid regulating function and mechanism of pseudo-ginseng powder is reported by the Dong Jing and the like, and the research proves that the pseudo-ginseng powder obviously reduces the TC, TG and LDL-C levels and the AST and ALT activities in the serum of hyperlipidemic rats; the histological observation result shows that the panax notoginseng powder obviously reduces the liver injury and fatty liver; the molecular level result shows that the pseudo-ginseng powder can up-regulate LDLR and SIRT1 and down-regulate LXR-alpha gene expression. Meanwhile, the pseudo-ginseng powder obviously reduces the protein expression of SREBP-2 and SCAP. The conclusion that the panax notoginseng powder has the functions of regulating blood fat and protecting the liver is probably related to the mechanism that the panax notoginseng powder up regulates SIRT1, down regulates LXR-alpha gene expression, further down regulates SCAP/SREBP-2 signal channels to inhibit cholesterol synthesis, and up regulates the gene expression of LDLR to improve the intake of LDL-C in blood circulation by the liver. In addition, the existing research also shows that the pseudo-ginseng can inhibit the proliferation of rat vascular smooth muscle cells stimulated by high-fat serum, and the effects of reducing blood fat and preventing atherosclerosis are proved.
In view of the above research background, the inventors believe that the active ingredients in ginseng and panax notoginseng are mainly saponins, which contain polysaccharide groups, and wet granulation is likely to cause the saponin extract to absorb moisture, thereby shortening the shelf life. The stability and activity of saponin components can be well guaranteed by dry granulation, but polysaccharide groups can be adhered to the surface of the granulator in the dry rolling process, so that the waste of raw materials is caused.
Disclosure of Invention
Based on the technical background, the invention aims to provide a pharmaceutical composition with an auxiliary blood fat reducing effect, which comprises a ginseng extract and a pseudo-ginseng extract, wherein active ingredients in ginseng and pseudo-ginseng can be effectively extracted by optimizing an extraction mode, and the extracted composition has good processing performance and can be well applied to dry granulation.
In a first aspect of the present invention, a composition for assisting blood lipid reduction is provided, the composition includes a ginseng extract and a panax notoginseng extract, and a preparation method of the ginseng extract includes: lyophilizing the alcoholic extract of Ginseng radix; the preparation of the pseudo-ginseng extract comprises the following steps: extracting lyophilized Notoginseng radix with ethanol.
In the composition of the first aspect, the mass ratio of the ginseng extract to the panax notoginseng extract is 1-6: 1-3, specifically, the mass ratio of the ginseng extract to the pseudo-ginseng extract is 4: 1, or 2: 1, or 1: 1, or 6: 1, or 2: 3.
preferably, the ginseng is one of, but not limited to, wild ginseng and mountain ginseng. As known in the art, the wild ginseng has the best medicinal effect, but the wild ginseng is scarce in quantity, the wild ginseng and the wild ginseng grow in the wild forest environment in the same way, and the components and the effects are close to those of the wild ginseng, so the ginseng is the wild ginseng in the forest in the preferred scheme of the invention.
Preferably, the ginseng product is Jilin or Liaoning, and further, the ginseng product comprises one or the combination of Jilin Tonghua, Liaoning New Bin and Liaoning Benxi; the growth period of the ginseng is preferably 10 years or more, and more preferably 15 years or more.
The ginseng extract according to the first aspect is preferably prepared by the following method: adding Ginseng radix into alcoholic solution, heating, reflux extracting, concentrating to obtain extract, and freeze drying to obtain lyophilized powder.
In the scheme, the alcohol solution is preferably a methanol solution or an ethanol solution, and further, the extraction of the total ginsenoside by the ethanol solution has a good effect, the concentration of the ethanol solution is 70-80%, the total reflux extraction time is 80-100 min, and the extraction times are 2-4.
The times of the heating reflux extraction are preferably three times, and the total extraction time is 90-100 min.
Preferably, the dosage of the ethanol solution is 8-10 times of the mass of the ginseng.
In the preparation process of the ginseng extract, the invention firstly proves that the transfer rate of the saponin components can be effectively improved by adopting the alcoholic solution for extraction. In the process research of drying the extracting solution, the invention discovers that the viscosity of the dried extract can be effectively reduced by adopting a freeze-drying mode, and further discovers that the loss of saponin components can be effectively reduced and the volatilization effect of polysaccharide components can be increased by adopting a stepped heating or cooling mode in the freeze-drying process.
In the above scheme, the freeze drying adopts a step-type cooling or heating, and the specific steps are as follows: and (3) carrying out reduced pressure concentration on the alcohol extract to obtain an extract, prefreezing the extract for 4-6 hours in an environment of-25 to-40 ℃, putting the extract into a freeze dryer, keeping the temperature at-25 to-30 ℃ for 1.5-2.5 hours, vacuumizing to 40-60pa, heating to the temperature of a shelf at-18 to 22 ℃, maintaining for 10-14 hours, heating to the temperature of-8 to 12 ℃, maintaining for 5-7 hours until sublimation is finished, heating the shelf to 38-42 ℃ until resolution is finished, and discharging.
In addition, in the embodiment of the first aspect, the preparation method of the notoginseng extract is as follows: freeze drying Notoginseng radix, pulverizing into coarse particles, reflux extracting with ethanol solution to obtain extractive solution, concentrating under reduced pressure to obtain extract, and spray drying to obtain spray dried powder.
In the scheme, the pseudo-ginseng is preferably Yunnan wenshan pseudo-ginseng, and the pseudo-ginseng with the growth life of seven years or more is preferably selected.
Preferably, the diameter of the coarse particles is 0.1-0.2 cm.
Preferably, the concentration of the ethanol solution is 65-75%, further 68-71%, and in a specific example, 70%; the amount of the ethanol solution is 5-9 times of the mass of the pseudo-ginseng.
Preferably, the total reflux extraction time of the ethanol solution is 50-70 min, and the extraction times are 1-3 times.
Preferably, the extraction solution is searched and concentrated at a lower temperature to obtain an extract, wherein the lower temperature is 55-65 ℃, and the density of the extract is 1.1-1.20.
In a second aspect of the present invention, a product for assisting blood lipid reduction is provided, wherein the product comprises the pharmaceutical composition of the first aspect and a pharmaceutical carrier.
Preferably, the auxiliary blood fat reducing product is one of health products, medicines and special medical foods; further preferably, the auxiliary blood fat reducing product is a medicament.
The above-mentioned embodiment as an auxiliary hypolipidemic agent includes the case where the composition of the first aspect is prepared together with other active ingredients, and also includes the case where the composition of the first aspect is used alone as an active ingredient; in the above preparation cases, the composition accounts for 1-99% of the total amount of the drug, and the dosage of the active ingredient is the technical content that can be conventionally determined by those skilled in the art according to the purpose of use. In other embodiments, the amount of the drug is from about 0.5mg/kg body weight/day to about 50mg/kg body weight/day.
The dosage form of the medicine is a unit dosage form suitable for single administration of accurate dosage, and comprises oral liquid preparations such as decoction, suspension, syrup, mixture, tincture and the like, and can also be ointment, granules, pills (honeyed pills, water pills, paste pills, wax pills and concentrated pills), powder, tablets (enteric-coated tablets, film-coated tablets, sugar-coated tablets, extract tablets, dispersible tablets, scratch tablets), capsules or drops and the like; further, the medicine is a tablet or a capsule.
In one embodiment, the medicament is a tablet, which further comprises a flavoring agent, a preservative, and a filler; considering that the medicine is applied to patients with hyperlipidemia, the flavoring agent is xylitol, and the specific preparation method is as follows: the composition of the first aspect, xylitol and citric acid are evenly mixed and then dry granulated.
In another embodiment, the medicament is a capsule, and the preparation method of the capsule is as follows: dry granulation of the composition of the first aspect followed by encapsulation.
In a third aspect of the present invention, there is provided a method for reducing blood lipid, the method comprising administering the composition of the first aspect, or the auxiliary blood lipid-lowering product of the second aspect, to an individual in need thereof.
In the embodiment of the third aspect, the subject in need thereof includes but is not limited to subjects in need of treatment, improvement or prevention, and health care, and the dosage of the drug required for the above application is a routine adjustment that can be made by medical staff according to the administration target.
The beneficial effects of one or more technical schemes are as follows:
1. in one embodiment of the invention, the composition with the effect of assisting in reducing blood fat comprises ginseng extract and pseudo-ginseng extract. The existing research results show that the ginsenoside and the notoginsenoside both have certain blood fat reducing activity, but the mechanisms for regulating blood fat of the substances have certain difference, and the blood fat reducing effect can be effectively improved by compounding the substances. Therefore, the invention firstly provides a composition of ginseng extract and pseudo-ginseng extract, and the composition of ginseng extract and pseudo-ginseng extract can exert good blood fat reducing effect through the combination of the ginseng extract and the pseudo-ginseng extract.
2. In another embodiment of the present invention, there is also provided an extraction process of ginseng extract and notoginseng extract, and in view of the purpose of the present invention, it is further intended to provide an extract suitable for dry granulation, wherein the extraction process of the present invention is designed to reduce interference of polysaccharide on the granulation process by optimizing the extraction method and the drying process, and to provide a hypolipidemic composition having a simple preparation process and better industrial performance.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
As introduced in the background art, ginseng and pseudo-ginseng have good blood fat reducing effect, and dry granulation is adopted to effectively improve the stability of saponin active ingredients in the medicinal materials, but the saponin extract is usually interfered by polysaccharide ingredients and is easily adhered to the mechanical edge in the processing stage.
In order to make the technical solution of the present invention more clearly understood by those skilled in the art, the technical solution of the present invention will be described in detail below with reference to specific examples and comparative examples.
Example 1 examination of extraction Process
First, investigation of extraction process of mountain ginseng extract under forest
1. Raw material screening
Selecting wild ginseng of Liaoning and Jilin with different growth years, and determining saponin content. The most suitable raw material for producing the wild ginseng under forest is preferably selected.
TABLE 1 screening of raw materials for different varieties of ginseng
And (4) conclusion: the content of wild ginseng under the forest, which is regulated by Landmark in Liaoning province, is more than or equal to 4.5 percent of total saponins, the total content of ginsenoside Rg1 and ginsenoside Re is not less than 0.61 percent, and the content of ginsenoside Rb1 is not less than 0.41 percent. Selecting wild ginseng in forest for more than 15 years as raw material.
2. Screening by extraction
Taking the wild ginseng under the forest in the same producing area and the same growth period, respectively extracting by adopting different extraction modes, and screening the optimal extraction mode by taking the extraction rate of the total saponins as an index.
(1) Water extraction: taking 100g of mountain ginseng under forest, adding purified water of 8 times of the raw materials, heating and refluxing for 2 hours, filtering, adding purified water of 6 times of the filter residue, heating and refluxing for 1 hour, filtering, combining the filtrates, and freeze-drying to obtain freeze-dried powder;
(2) alcohol extraction: taking 100g of mountain ginseng under forest, adding 95% ethanol in an amount which is 8 times that of the raw materials, heating and refluxing for 2 hours, filtering, adding 95% ethanol in an amount which is 6 times that of the filter residue, heating and refluxing for 1 hour, filtering, combining the filtrates, and freeze-drying to obtain the freeze-dried powder.
TABLE 2 Total saponins extraction yield without extraction process
And (4) conclusion: the extraction rate of the total ginsenoside in the alcohol extraction mode is obviously higher than that in the water extraction mode, and the alcohol extraction mode is selected for extraction.
3. Screening of extraction Process
And (3) adopting an orthogonal test to investigate the extraction solvent, the extraction time and the extraction frequency of the alcohol extraction process of the mountain ginseng extract under forest.
TABLE 3 factor level table
TABLE 4 results of orthogonal experiments
TABLE 5 ANOVA TABLE
And (4) conclusion: by using L9(34) Orthogonal test, taking the extraction rate of total saponins of panax ginseng as an investigation index, carrying out visual analysis, and displaying the results that k2 is more than k3 is more than k1 in factor A, k2 is more than k1 is more than k3 in factor B, k3 is more than k1 is more than k2 in factor C, k3 is more than k2 is more than k1 in factor D, R value is A is more than D is more than C is more than B, namely the influence sequence of all factors is ethanol concentration, extraction frequency, extraction time and solvent amount, so the optimal extraction combination is A2B2C3D3However, since only the ethanol concentration and the extraction frequency have significance on the influence of the extraction rate of the total saponins of panax ginseng, the finally determined extraction process is A2B1C1D3。
4. Freeze-drying process
Taking the mountain ginseng extract under forest, pre-freezing the mountain ginseng extract in an environment of-25 to-40 ℃ for 5 hours, putting the mountain ginseng extract into a freeze dryer, keeping the mountain ginseng extract at-25 to-30 ℃ for 2 hours, vacuumizing the mountain ginseng extract to 40 to 60pa, then heating the mountain ginseng extract to the temperature of-20 ℃ on a shelf, keeping the temperature for 12 hours, then heating the mountain ginseng extract to-10 ℃ on the shelf, keeping the temperature for 6 hours until sublimation is finished, heating the mountain ginseng extract to 40 ℃ on the shelf again until resolution is finished, and discharging the mountain ginseng extract.
5. Process for determining freeze-dried powder of mountain ginseng under forest
Taking 500g of wild ginseng under forest, adding 4800g of 75% ethanol, carrying out reflux extraction for 30min, filtering, adding 4800g of 75% ethanol into filter residues, filtering, extracting for 3 times in total, combining filtrates to obtain 15120g of filtrate, concentrating under reduced pressure at 60 ℃ to 510g of extract with the density of 1.20-1.30, putting the extract into a tray, pre-freezing for 5 hours at (-25 ℃ to-40 ℃), putting into a freeze dryer, keeping at-25 ℃ to-30 ℃ for 2 hours, vacuumizing to 40-60pa, heating to-20 ℃ of the shelf temperature, keeping for 12 hours, heating to-10 ℃ of the shelf temperature, keeping for 6 hours until sublimation is finished, heating to 40 ℃ of the shelf temperature until resolution is finished, discharging, crushing, and sieving with a 100-mesh sieve to obtain 250g of wild ginseng freeze-dried powder under forest.
6. Quality control
6.1 mass:
TABLE 6
6.2 the detection method of the total saponins comprises the following steps:
6.2.1 reagents
Amberlite-XAD-2 macroporous resin, sigma chemical, u.s.a.
And n-butanol is analyzed and purified.
The ethanol is analyzed and purified.
The neutral alumina is used for chromatography, 100-200 meshes.
Ginsenoside Re was purchased from China institute for drug and biological products.
Weighing 5g of vanillin in the vanillin solution, adding glacial acetic acid to dissolve the vanillin solution, and fixing the volume to 100 mL.
Perchloric acid analysis of alcohols
Glacial acetic acid analytically pure
Ginsenoside Re standard solution: accurately weighing 0.020g of ginsenoside Re standard substance, dissolving with methanol, and diluting to 10.0mL, namely, each milliliter contains 2.0mg of ginsenoside Re.
6.2.2 instruments
Colorimeter and chromatographic column
6.2.3 Experimental procedures
Sample treatment: weighing about 1.000g of sample (according to the amount of ginseng contained in the sample), placing the sample in a 100mL volumetric flask, adding a small amount of water, carrying out ultrasonic treatment for 30min, then adding water to fix the volume to 100mL, shaking up, placing, and absorbing 1.0mL of supernatant for column chromatography.
Column chromatography: a10 mL syringe was used as a chromatography tube, and 3cm Amberlite-XAD-2 macroporous resin was placed therein, followed by addition of 1cm neutral alumina. Washing the column with 25mL of 70% ethanol, discarding the eluent, washing the column with 25mL of water, discarding the eluent, accurately adding 1.0mL of the treated sample solution, washing the column with 25mL of water, discarding the eluent, eluting ginsenoside with 25mL of 70% ethanol, collecting the eluent in an evaporation dish, and placing in a water bath at 60 ℃ to volatilize, thereby performing color development.
Color development: accurately adding 5% vanillin glacial acetic acid solution into the evaporated evaporation pan, rotating the evaporation pan to completely dissolve the residue, adding 0.8mL perchloric acid, mixing, transferring into 5mL centrifuge tube with plug, heating in water bath at 60 deg.C for 10min, taking out, cooling in ice bath, accurately adding glacial acetic acid 5.0mL, shaking, and performing colorimetric determination with standard tube at 560nm wavelength in 1cm cuvette.
Standard tubes: absorbing 100 μ l ginsenoside Re standard solution (2.0mg/mL) in an evaporation dish, evaporating in water bath (below 60 deg.C), or drying with hot air (without overheating), and determining absorbance value. 6.2.4 calculation:
in the formula:
x: the total saponin content (calculated by ginsenoside Re) in the sample is g/100 g;
a1: absorbance value of the measured liquid
A2: absorbance value of standard liquid
C: amount of Standard tube ginsenoside Re, μ g
V: sample dilution volume, mL
M: sample mass, g
The result of the calculation retains two significant digits.
Second, study of the extract technology of Panax notoginseng
Notoginseng radix total saponin is the main effective component of Notoginseng radix, and can be used for preventing and treating hyperlipidemia. The invention selects fresh panax notoginseng as raw material, and examines the extraction process of panax notoginseng by taking the extraction rate of panax notoginseng saponins as an index.
1. Raw material screening
1.1 years of growth investigation
Selecting Notoginseng radix from Yunnan Wenshan with different growth years, and determining Notoginseng radix total saponin content. The pseudo-ginseng raw material which is most suitable for production is preferably selected.
TABLE 7
And (4) conclusion: with the increase of the growth period of 3-9 years of panax notoginseng, the content of panax notoginseng saponins tends to increase year by year, the increase amplitude decreases year by year after 7 years, and the content of total saponins tends to decrease after 10 years. The pseudo-ginseng is sold in 3-7 years in the market, and the cost is high after 7 years, so that 7-year-old pseudo-ginseng is finally selected as a raw material.
1.2 examination of drying
Most of the commercial panax notoginseng is dried by adopting a drying or sun-drying processing mode, and as the optimal drying mode, 7-year-old fresh panax notoginseng is selected, and the fresh panax notoginseng is processed by adopting different drying modes and the content of panax notoginseng saponins is respectively measured.
TABLE 8
And (4) conclusion: according to the determination result, the panax notoginseng saponins are lost to a certain extent no matter which drying mode is adopted, especially drying is carried out, the content loss is large, the drying time is long, and the loss of the panax notoginseng saponins is minimum, so that 7-year-old freeze-dried panax notoginseng is finally selected as the raw material of the panax notoginseng extract.
2. Investigation of extraction Process
Extracting Notoginseng radix extract from lyophilized Notoginseng radix crushed into coarse particles (diameter of 0.1-0.2cm) by ethanol reflux extraction, and selecting the best extraction method for Notoginseng radix extract.
TABLE 9 factor level table
TABLE 10 results of orthogonal experiments
TABLE 11 ANOVA TABLE
And (4) conclusion: by using L9(34) Orthogonal test, using the extraction rate of panax notoginseng saponins as an investigation index to carry out visual analysis, and displaying the result that k2 is more than k3 is more than k1 in the factor A, k2 is more than k3 is more than k1 in the factor B, k3 is more than k2 is more than k1 in the factor C, and R value is A is more than B is more than C, namely the influence sequence of all factors is ethanol concentration is more than extraction time and more than extraction times, so the optimal extraction combination is A2B2C3However, because the influence of the concentration of only ethanol on the extraction rate of the panax notoginseng saponins is significant, the finally determined extraction process is A2B2C2。
3. Drying
Concentrating Notoginseng radix extractive solution at low temperature (60 deg.C) under reduced pressure to obtain thick extract (density of 1.1-1.20), and spray drying to obtain spray dried powder.
4. Process for determining notoginseng extract
Collecting coarse powder of lyophilized Notoginseng radix with diameter of 0.1-0.2cm (500 g), extracting with 70% ethanol (4000 g) under reflux for 60min, filtering, extracting residue with 3000g 70% ethanol under reflux for 60min, filtering, and mixing the filtrates to obtain filtrate 7265 g. Concentrating the filtrate at low temperature (60 deg.C) under reduced pressure to obtain extract with density of 1.1-1.20, to obtain 267g extract, and spray drying to obtain spray dried powder 125 g.
Third, investigation of composition ratio
Selecting different formulation ratios of the ingredients of the Sanxia mountain ginseng and the pseudo-ginseng respectively to perform experiments of improving the hyperlipidemia of experimental rats, and preferably selecting the optimal formulation ratio
1 materials and methods
1.1 animals, materials and reagents
Healthy SPF grade adult male SD rats, 84, were weighing (200 ± 20) g at the end of the acclimation period. The breeding is carried out in cages, each cage is provided with 3 cages, and the feeding and drinking water are free. The temperature range of the animal feeding laboratory is (25 +/-1) DEG C, the relative humidity is 50-60%, and the light and dark alternating time of day and night is 12 h.
TABLE 12 samples of mountain ginseng and notoginseng in different proportions
Freeze dried mountain ginseng powder and notoginseng extract.
TC, TG, HDL-C, LDL-C test cassettes, purchased from Hippocampus Kazaki Kaisha (Xiamen) science and technology Co.
Control group feed: the feed is maintained, and the requirement of rodent growth and development can be met;
model group feed: the maintenance feed is added with 20.0 percent of cane sugar, 15.0 percent of lard, 1.2 percent of cholesterol, 0.2 percent of sodium cholate, and proper amount of casein, calcium hydrophosphate, stone powder and the like. Except for the crude fat, the water content, crude protein, crude fat, crude fiber, crude ash, calcium and phosphorus of the model feed all reach the national standards of maintaining the feed.
1.2 instruments and devices
High speed refrigerated centrifuge (Thermo Fisher corporation); metler tloedo Pl303 electronic analytical balance (Shanghai Merle-Teledo, Inc.); an electric heating constant temperature water bath (Beijing Changan scientific instruments Co., Ltd.); type 722 spectrophotometer (shanghai precision scientific instruments ltd); vortex mixer (Shanghai Jingke industries, Ltd.).
1.3 methods
1.3.1 dose grouping and test sample administration time
Male SD rats, 84, were divided into 7 experimental groups of 12 animals each. 5 sample groups, 1 blank control group and 1 model control group with different proportions of the mountain ginseng and the pseudo-ginseng under forest are established in the experiment. The test sample was given for 28 days.
1.3.2 animal modeling, grouping and administration
1.3.3 Adaptation period
Rats were fed maintenance feed under a barrier system for 7 d.
1.3.4 moulding phase
The animals were randomly divided into 2 groups according to body mass, and 12 rats were fed with maintenance feed as a blank control group and 72 rats were fed with model feed as a model group. Body weight was weighed 1 time per week.
After the model group is fed with model feed for 2 weeks, the rats of the blank control group and the model group are fasted to take blood (tail), serum is separated as soon as possible after blood taking, and the TC, TG and LDL-C, HDL-C contents of the serum are determined. The model groups are randomly divided into 5 groups of 12 according to the TC content, and the TC, TG and LDL-C, HDL-C content difference of each group is compared after the grouping.
1.3.5 test sample administration
After successful modeling and grouping, 5 dose groups are intragastrically administered with panax notoginseng samples with different proportions every day, and a blank control group and a model control group are intragastrically administered with distilled water with the same volume every day. The gavage amount is 1mL/(100 g.d). The blank control group was continued to be given maintenance feed, and the model control group and 5 sample groups were continued to be given model feed. Each mouse was weighed and recorded 1 time per week, and the gavage amount was adjusted according to the body mass. The rats were observed daily for appetite behavior, status, hair and animal death.
1.3.6 sample Collection and related serum index detection
At the end of the experiment, rats are fasted for 12 hours without water prohibition, blood is collected from femoral artery, and centrifugation is carried out for 10min at 3000 r/min. And (4) sucking the serum, and detecting the contents of TC, TG and HDL-C, LDL-C in the serum according to the kit specification.
1.4 statistical results
All experimental data are as follows
And (4) showing. SPSS 13.0 software is adopted to carry out one-factor variance analysis, and P less than 0.05 represents statistical significance.
Fourthly, the result and analysis of the drug effect of the composition
As shown in Table 13, compared with the blank control group, the serum TC and LDL-C, TG content of the rats in the model control group are both increased remarkably (P < 0.01) and the serum HDL-C content of the rats in the model control group is reduced remarkably (P < 0.01). Compared with a model control group, the contents of TC and LDL-C, HDL-C, TG in rat serum and the contents of LDL-C, HDL-C, TG in different proportions of the wild ginseng and the pseudo-ginseng have no obvious change (P is more than 0.05), but are improved to different degrees, wherein the proportion of the wild ginseng to the pseudo-ginseng is 1: 2, the blood fat improvement is most obvious.
TABLE 13 influence of fresh Underwood Panax schinseng C.A. Meyer product on blood lipid content of high lipid model rat (+ -s, n-12)
Note: the difference was very significant compared to the blank control group (P < 0.01).
Fifth, conclusion
When the ratio of mountain ginseng to pseudo-ginseng under forest is 1: 2 (equivalent to raw medicinal materials), the degree of improving the blood fat of experimental rats is most obvious, although no significant difference is found compared with model groups, the trend of improving the blood fat state is obvious, each group is improved in different degrees, the product effect is exact, and the method is worthy of popularization.
Example 2
In the embodiment, an auxiliary hypolipidemic tablet is provided, and the preparation method of the tablet comprises the following steps: uniformly mixing 250g of mountain ginseng freeze-dried powder (equivalent to 500g of fresh mountain ginseng), 250g of pseudo-ginseng extract (equivalent to 1000g of freeze-dried pseudo-ginseng), 85g of xylitol and 10g of citric acid, and performing dry granulation, wherein the granulation parameters are as follows: feeding at 35rpm, pressing at 6rpm, pressing at 35bar, discharging at 100rpm, sieving with 0.8mm sieve, adding magnesium stearate 5g, mixing, tabletting, and making into tablet 0.6 g/tablet to obtain 1000 tablets.
Example 3
In the embodiment, a capsule for assisting in reducing blood fat is provided, and the preparation method of the capsule comprises the following steps: uniformly mixing 250g of mountain ginseng freeze-dried powder (equivalent to 500g of fresh mountain ginseng) and 250g of pseudo-ginseng extract (equivalent to 1000g of freeze-dried pseudo-ginseng), and performing dry granulation, wherein the granulation parameters are as follows: feeding at 35rpm, pressing at 6rpm, pressing at 35bar, discharging at 100rpm, and sieving with 0.8mm sieve, encapsulating to obtain capsule, and making into capsule at 0.5 g/capsule to obtain 1000 granules.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The composition for assisting in reducing blood fat is characterized by comprising a ginseng extract and a pseudo-ginseng extract, and the preparation method of the ginseng extract comprises the following steps: lyophilizing the alcoholic extract of Ginseng radix; the preparation of the pseudo-ginseng extract comprises the following steps: extracting lyophilized Notoginseng radix with ethanol.
2. The composition for assisting in reducing blood fat according to claim 1, wherein the mass ratio of the ginseng extract to the panax notoginseng extract in the composition is 1-6: 1-3, specifically, the mass ratio of the ginseng extract to the pseudo-ginseng extract is 4: 1, or 2: 1, or 1: 1, or 6: 1, or 2: 3.
3. the composition for assisting in reducing blood lipid according to claim 1, wherein the ginseng is one of, but not limited to, wild ginseng, mountain ginseng under forest; preferably, the ginseng is mountain ginseng under forest;
preferably, the ginseng product is Jilin or Liaoning, and further, the ginseng product comprises one or the combination of Jilin Tonghua, Liaoning New Bin and Liaoning Benxi; the growth period of the ginseng is preferably 10 years or more, and further, the ginseng is a wild ginseng under forest which grows for 15 years or more.
4. The composition for assisting in reducing blood lipid according to claim 1, wherein the ginseng extract is prepared by the following method: adding Ginseng radix into alcoholic solution, heating, reflux extracting, concentrating to obtain extract, and freeze drying to obtain lyophilized powder.
5. The composition for assisting in reducing blood lipid according to claim 4, wherein the alcohol solution is preferably a methanol solution or an ethanol solution, and further, the extraction of the total ginsenoside by the ethanol solution has a good effect, the concentration of the ethanol solution is 70-80%, the total reflux extraction time is 80-100 min, and the extraction times are 2-4 times;
or the number of times of heating reflux extraction is preferably three, and the total extraction time is 90-100 min;
or the dosage of the ethanol solution is 8-10 times of the mass of the ginseng.
6. The composition for assisting in reducing blood lipid according to claim 4, wherein the freeze-drying adopts a stepwise temperature reduction or temperature rise, and the specific steps are as follows: and (3) carrying out reduced pressure concentration on the alcohol extract to obtain an extract, prefreezing the extract for 4-6 hours in an environment of-25 to-40 ℃, putting the extract into a freeze dryer, keeping the temperature at-25 to-30 ℃ for 1.5-2.5 hours, vacuumizing to 40-60pa, heating to the temperature of a shelf at-18 to 22 ℃, maintaining for 10-14 hours, heating to the temperature of-8 to 12 ℃, maintaining for 5-7 hours until sublimation is finished, heating the shelf to 38-42 ℃ until resolution is finished, and discharging.
7. The composition for assisting in reducing blood lipid according to claim 1, wherein the notoginseng extract is prepared by the following method: freeze drying Notoginseng radix, pulverizing into coarse particles, reflux extracting with ethanol solution to obtain extractive solution, concentrating under reduced pressure to obtain extract, and spray drying to obtain spray dried powder;
preferably, the pseudo-ginseng is preferably Yunnan wenshan pseudo-ginseng, and the pseudo-ginseng with the growth life of seven years or more is preferably selected;
preferably, the diameter of the coarse particles is 0.1-0.2 cm;
preferably, the concentration of the ethanol solution is 65-75%, further 68-71%, and in a specific example, 70%; the amount of the ethanol solution is 5-9 times of the mass of the pseudo-ginseng;
preferably, the total reflux extraction time of the ethanol solution is 50-70 min, and the extraction times are 1-3 times;
preferably, the extraction solution is searched and concentrated at a lower temperature to obtain an extract, wherein the lower temperature is 55-65 ℃, and the density of the extract is 1.1-1.20.
8. A product for assisting in reducing blood lipid, comprising the pharmaceutical composition of any one of claims 1 to 7 and a pharmaceutically acceptable carrier;
preferably, the auxiliary blood fat reducing product is one of health products, medicines and special medical foods; furthermore, the auxiliary blood fat reducing product is a medicine;
the dosage form of the medicine is a unit dosage form suitable for single administration of accurate dosage, and comprises oral liquid preparations such as decoction, suspension, syrup, mixture, tincture and the like, ointment, granules, pills, powder, tablets, capsules or drops; further, the medicine is a tablet or a capsule.
9. The product of claim 8, wherein the pharmaceutical is a tablet, and the tablet further comprises flavoring agents, preservatives, and fillers;
preferably, the flavoring agent is xylitol, and the specific preparation method is as follows: mixing the composition of any one of claims 1-7, xylitol, and citric acid, and granulating by dry method;
preferably, the medicine is a capsule, and the preparation method of the capsule comprises the following steps: dry granulation of the composition according to any of claims 1 to 7 followed by encapsulation.
10. A method of reducing blood lipids, comprising administering to a subject in need thereof a composition according to any one of claims 1-7, or a supplemental blood lipid lowering product according to claim 8 or 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111657410.XA CN114209723B (en) | 2021-12-30 | 2021-12-30 | Composition for assisting in reducing blood fat, product containing composition and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111657410.XA CN114209723B (en) | 2021-12-30 | 2021-12-30 | Composition for assisting in reducing blood fat, product containing composition and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114209723A true CN114209723A (en) | 2022-03-22 |
| CN114209723B CN114209723B (en) | 2023-10-03 |
Family
ID=80707196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111657410.XA Active CN114209723B (en) | 2021-12-30 | 2021-12-30 | Composition for assisting in reducing blood fat, product containing composition and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114209723B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1370472A (en) * | 2002-01-25 | 2002-09-25 | 云南省天然药物中心 | Health food with blood pressure and blood lipoid regulating function and its production process |
| CN104490967A (en) * | 2014-12-06 | 2015-04-08 | 云南云药医药研究有限公司 | High-efficiency high-yield preparation method of panax notoginseng extract |
| CN109985079A (en) * | 2017-12-29 | 2019-07-09 | 辽宁上药科技开发有限公司 | A kind of preparation method and application comprising ginseng and sanchi flower double-layer tablets |
| CN112618560A (en) * | 2021-02-08 | 2021-04-09 | 北京泛亚同泽生物医学研究院有限公司 | Pharmaceutical composition containing ginsenoside and application thereof in reducing blood fat and inhibiting fatty liver |
-
2021
- 2021-12-30 CN CN202111657410.XA patent/CN114209723B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1370472A (en) * | 2002-01-25 | 2002-09-25 | 云南省天然药物中心 | Health food with blood pressure and blood lipoid regulating function and its production process |
| CN104490967A (en) * | 2014-12-06 | 2015-04-08 | 云南云药医药研究有限公司 | High-efficiency high-yield preparation method of panax notoginseng extract |
| CN109985079A (en) * | 2017-12-29 | 2019-07-09 | 辽宁上药科技开发有限公司 | A kind of preparation method and application comprising ginseng and sanchi flower double-layer tablets |
| CN112618560A (en) * | 2021-02-08 | 2021-04-09 | 北京泛亚同泽生物医学研究院有限公司 | Pharmaceutical composition containing ginsenoside and application thereof in reducing blood fat and inhibiting fatty liver |
Non-Patent Citations (1)
| Title |
|---|
| 马声宏等: "田七人参茶治疗高血压病、高脂血症临床疗效观察", 《中成药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114209723B (en) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2451740C (en) | Composition comprising wenguanguo extracts, methods for preparing same and uses thereof | |
| CN104644882B (en) | Callicarpa nudiflora extract containing phenylethanoid glycosides and preparation method thereof | |
| JP2009542634A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising extract | |
| JP5514216B2 (en) | Pharmaceutical composition for prophylaxis and treatment of inflammatory diseases containing ethyl acetate fraction of dried chow stone extract as active ingredient, and method for producing the fraction | |
| US7799353B2 (en) | Pharmaceutical mixture for hepatitis treatment and its preparation method | |
| CN101897740A (en) | Glabrous sarcandra herb formula particle and preparation method thereof | |
| CN102302615B (en) | Effective site group of daphne giraldii nitsche leaf, preparation method, medicinal composition and application thereof | |
| CN114209723B (en) | Composition for assisting in reducing blood fat, product containing composition and application | |
| CN101712618B (en) | Two crystal form materials of salvianolic acid A, preparation method as well as medicine compound and application thereof | |
| CN109985079B (en) | Preparation method and application of double-layer tablet containing ginseng and pseudo-ginseng flower | |
| CN101081250B (en) | Potygonum multiflorum thunb extract medicament for treating anemia and the preparing method thereof | |
| CN105535533A (en) | Traditional Chinese medicine composition for treatinggastritis | |
| CN1209155C (en) | Balsam pear products containing multiple hypoglycemic active composition and preparation thereof | |
| CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
| CN102641342A (en) | Traditional Chinese medicine extract for treating nephropathy and preparation method | |
| CN100434092C (en) | Prescription containing sweet clover component and its formulation | |
| CN105982998B (en) | A kind of pharmaceutical composition and its preparation method and application for treating fatty liver | |
| CN114377030B (en) | Pharmaceutical composition of chicoric acid and echinacoside and application thereof | |
| CN109985080B (en) | Preparation method and application of double-layer tablet containing ginseng and acanthopanax sessiliflorus | |
| CN1220509C (en) | Chinese patent medicine for curing cardiovascular disease, its preparation method and quality control method | |
| KR102136484B1 (en) | Composition for preventing or treating liver injury and method for preparing the same | |
| CN113694103B (en) | Traditional Chinese medicine extract without glycyrrhizic acid, preparation method, pharmaceutical preparation and application | |
| CN107496476A (en) | The beneficial liver effect of yunna cowparsnip and application technology | |
| CN107252440A (en) | A kind of preparation method and purposes of the Hickory Leaves general flavone with hypoglycemic effect | |
| CN1460510A (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |